Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D M SavareseN J Vogelzang

Abstract

To investigate the combination of docetaxel, estramustine (EM), and low-dose hydrocortisone in men with hormone-refractory prostate cancer (HRPC). Combinations of EM with other antimitotic agents such as docetaxel are synergistic in vitro and show significant clinical activity in patients with HRPC. We studied intravenous administration of docetaxel 70 mg/m(2), oral estramustine, and low-dose daily hydrocortisone in men with HRPC who demonstrated progression after initial hormone therapy. Of the 47 men enrolled onto this multicenter cooperative group study, 46 were assessable for response and/or toxicity. In the 24 patients with measurable disease, there were three complete and nine partial responses for a measurable disease response rate of 50% (12 of 24 patients; 95% confidence interval [CI], 27% to 73%). In the 44 patients in whom pretreatment prostate-specific antigen (PSA) was elevated, 30 (68%) had a 50% or greater decrease, and 25 (57%) had a 75% or greater decrease in PSA. The combined measurable disease and biochemical response rate in all 46 assessable patients was 54% (three complete responses, 22 partial responses, 95% CI, 37% to 71%). The predominant toxicity was neutropenia, with 26% of patients having grade 3 and...Continue Reading

References

Feb 20, 1991·Journal of the National Cancer Institute·I Ringel, S B Horwitz
Feb 1, 1991·The Journal of Urology·G J MontagneP J Klopper
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K J PientaL E Flaherty
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I Scher, W K Kelly
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E J Small, N J Vogelzang
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R HudesC McAleer
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D P PetrylakC A Olsson
Mar 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W KreisV Vinciguerra
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang

❮ Previous
Next ❯

Citations

Sep 17, 2002·British Journal of Cancer·R PetrioliG Francini
Jun 27, 2002·Current Urology Reports·Tomasz M Beer, Joseph S Bubalo
May 21, 2003·American Journal of Therapeutics·Robert J BehrensWilliam L Dahut
Oct 9, 2003·The Journal of Urology·Masood A KhanAlan W Partin
Dec 24, 2003·Cancer·Nicholas J VogelzangEverett E Vokes
Aug 31, 2004·Japanese Journal of Clinical Oncology·Wen-Chyi SheenYung-Chang Lin
Mar 11, 2005·Expert Review of Anticancer Therapy·Teodoro SavaGian Luigi Cetto
Jul 13, 2006·Expert Review of Anticancer Therapy·Hak Choy
Jun 5, 2008·Cancer Immunology, Immunotherapy : CII·Tanja D de GruijlRik J Scheper
Aug 30, 2008·Wiener klinische Wochenschrift·Michael RauchenwaldMichael Krainer
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pascal MachielsJoseph Kerger
Apr 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan HalabiEric J Small
Mar 17, 2010·Expert Opinion on Investigational Drugs·Shreya Shah, Charles Ryan
Sep 23, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Rishi NayyarNarmada P Gupta
May 5, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Yoshihiro NakagamiMasaaki Tachibana
Jan 1, 2009·Therapeutic Advances in Medical Oncology·Tanya B DorffMaha H A Hussain
May 12, 2011·International Reviews of Immunology·Cheryl Lai-Lai ChiangGeorge Coukos
Sep 8, 2015·Vaccines·Cheryl Lai-Lai ChiangLana E Kandalaft
May 21, 2003·Current Urology Reports·Donald Trump, Yiu-Keung Lau
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William L DahutWilliam D Figg
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Mar 3, 2004·Prostate Cancer and Prostatic Diseases·J P CoxonR S Kirby
Feb 3, 2005·World Journal of Urology·Daniel P Petrylak
Feb 14, 2006·Nature Clinical Practice. Urology·Niklas J Mackler, Kenneth J Pienta
Apr 8, 2004·Current Opinion in Urology·Karl M Kasamon, Nancy A Dawson
Aug 8, 2006·American Journal of Clinical Oncology·Damian A LaberRenato V La Rocca
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J Roth
Apr 20, 2005·Cancer Chemotherapy and Pharmacology·Susan GoodinRobert S DiPaola
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary-Ellen TaplinMeredith M Regan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved